Who
John Bencich
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, AEON Biopharma; CEO, Achieve Life Sciences; V.P. and CFO, Trubion Pharmaceuticals.
In numbers
- Trades disclosed
- 85
- Buys
- 4
- Sells
- 3
- Bought
- $115K
- Sold
- $5,417
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 29 Jan 2010
- Last trade
- 2 Apr 2026
- Last filed
- 3 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Apr 2026filed 3 Apr 2026 | AEON AEON BiopharmaBiotechnology | SEC FORM 4 Code A | —754,717 at $0.00 | filing |
| 2 Apr 2026filed 3 Apr 2026 | AEON AEON BiopharmaBiotechnology | SEC FORM 4 Code A | —754,717 at $0.00 | filing |
| 16 Aug 2024filed 20 Aug 2024 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Code A | $18K5,000 at $3.67 | filing |
| 19 Apr 2024filed 23 Apr 2024 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 19 Apr 2024filed 23 Apr 2024 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 19 Apr 2024filed 23 Apr 2024 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Code F | $27K6,088 at $4.51 | filing |
| 4 Mar 2024filed 6 Mar 2024 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code P | —10,000 at $0.00 | filing |
| 4 Mar 2024filed 6 Mar 2024 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Bought | $46K10,000 at $4.59 | filing |
| 22 Jan 2024filed 24 Jan 2024 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 22 Jan 2024filed 24 Jan 2024 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 30 May 2023filed 1 Jun 2023 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Bought | $28K5,000 at $5.50 | filing |
| 28 Apr 2023filed 1 May 2023 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 28 Apr 2023filed 1 May 2023 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 28 Apr 2023filed 1 May 2023 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Code F | $15K1,827 at $8.29 | filing |
| 21 Apr 2023filed 25 Apr 2023 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Code F | $40K5,863 at $6.80 | filing |
| 21 Apr 2023filed 24 Apr 2023 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 21 Apr 2023filed 24 Apr 2023 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 21 Apr 2023filed 24 Apr 2023 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Code F | $50K7,324 at $6.80 | filing |
| 25 Jan 2023filed 27 Jan 2023 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 25 Jan 2023filed 27 Jan 2023 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026ACHV · manilatimes.net · 21 Oct 2026
0 headlines in the last 90 days name John Bencich; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.